Cambios

              
    

          
          
        
        

            
f
1
{
f
1
{
            
n
n
2
  "Observaciones": {
            
3
    "en": "",
            
4
    "es": "Turrini, Mauro; Bourgain, Catherine; 2021; Appraising 
            
5
screening, making risk in/visible. The medical debate over Non-Rare 
            
6
Thrombophilia (NRT) testing before prescribing the pill [DATASET]; 
            
7
DIGITAL.CSIC; http://dx.doi.org/10.20350/digitalCSIC/13972"
            
8
  },
            
2
  "author": null,
9
  "author": null,
            
3
  "author_email": null,
10
  "author_email": null,
            
n
n
11
  "autor": {
            
12
    "es": [
            
13
      "Mauro Turrini",
            
14
      "Catherine Bourgain"
            
15
    ]
            
16
  },
            
4
  "conforms_to": [],
17
  "conforms_to": [],
            
5
  "coverage_new": {},
18
  "coverage_new": {},
            
6
  "creator_user_id": "196556b3-e0c4-4c51-a9e6-f51cc752bc37",
19
  "creator_user_id": "196556b3-e0c4-4c51-a9e6-f51cc752bc37",
            
7
  "description": {
20
  "description": {
            
n
8
    "en": "Non-rare thrombophilias (NRT) are hereditary 
n
21
    "en": "",
            
9
predispositions to thromboembolism, the most severe side-effect of 
22
    "es": "The dataset includes: - a detailed description of the 
            
10
hormonal contraception. In the mid-1990s, the identification of NRT 
23
search procedure, the queries adopted, and selection criteria of 
            
11
stirred up a controversy over the possibility of investigating these 
24
selection exclusion (section #1); - the two original bibliographic 
            
12
genetic variants in women wishing to use contraception. Appraising how 
25
searches (section #2 & #3); - the final 21 articles selected coming 
            
13
to handle this test led the medical profession to reconfigure the risk 
26
from these searches and 7 additional articles coming from manual 
            
14
visibility on hormonal contraception. Through a review of scientific 
27
searches of literature reviews (section #4)."
            
15
literature, this paper reconstructs the debate over whether and how 

            
16
NRT genetic tests should enter the distribution system of 

            
17
pharmacological contraception. The main arguments concern their 

            
18
epidemiological, social, economic, and clinical consequences of these 

            
19
risk factors. We analyze this debate as a process consisting in 

            
20
shaping the risk visibility. To those who opt for selective 

            
21
thrombophilia screening, this test should become a part of the medical 

            
22
decision-making process, and its visibility should be kept under 

            
23
medical control to protect contraception safety. To advocates of 

            
24
universal or \u201cextended\u201d screening, NRT visibility becomes a 

            
25
moral/legal obligation, and the test a valuable, if not mandatory, 

            
26
means to assure contraception safety. Risk visibility reveals 

            
27
assumptions about medical power, women\u2019s responsibility, and drug 

            
28
safety, and points to an appraisal process as an ideal field to 

            
29
explore political and epistemological implications of screening.",

            
30
    "es": "Non-rare thrombophilias (NRT) are hereditary 

            
31
predispositions to thromboembolism, the most severe side-effect of 

            
32
hormonal contraception. In the mid-1990s, the identification of NRT 

            
33
stirred up a controversy over the possibility of investigating these 

            
34
genetic variants in women wishing to use contraception. Appraising how 

            
35
to handle this test led the medical profession to reconfigure the risk 

            
36
visibility on hormonal contraception. Through a review of scientific 

            
37
literature, this paper reconstructs the debate over whether and how 

            
38
NRT genetic tests should enter the distribution system of 

            
39
pharmacological contraception. The main arguments concern their 

            
40
epidemiological, social, economic, and clinical consequences of these 

            
41
risk factors. We analyze this debate as a process consisting in 

            
42
shaping the risk visibility. To those who opt for selective 

            
43
thrombophilia screening, this test should become a part of the medical 

            
44
decision-making process, and its visibility should be kept under 

            
45
medical control to protect contraception safety. To advocates of 

            
46
universal or \u201cextended\u201d screening, NRT visibility becomes a 

            
47
moral/legal obligation, and the test a valuable, if not mandatory, 

            
48
means to assure contraception safety. Risk visibility reveals 

            
49
assumptions about medical power, women\u2019s responsibility, and drug 

            
50
safety, and points to an appraisal process as an ideal field to 

            
51
explore political and epistemological implications of screening."

            
52
  },
28
  },
            
n
53
  "groups": [],
n
29
  "groups": [
            
30
    {
            
31
      "description": "",
            
32
      "display_name": "Estudios estad\u00edsticos",
            
33
      "id": "b644546a-96d3-486c-9130-673c3c4b8e23",
            
34
      "image_display_url": 
            
35
c.es/uploads/group/2024-09-23-113759.895456Estudios-estadisticos.png",
            
36
      "name": "estudios-estadisticos",
            
37
      "title": "Estudios estad\u00edsticos"
            
38
    }
            
39
  ],
            
54
  "id": "ede653fb-c1de-47f2-86cb-72b69563eb24",
40
  "id": "ede653fb-c1de-47f2-86cb-72b69563eb24",
            
55
  "identifier": "https://doi.org/10.20350/digitalCSIC/13972",
41
  "identifier": "https://doi.org/10.20350/digitalCSIC/13972",
            
n
n
42
  "international_spatial_translated": {
            
43
    "en": "",
            
44
    "es": ""
            
45
  },
            
56
  "isopen": false,
46
  "isopen": false,
            
57
  "issued_date": "2021-08-11T00:00:00",
47
  "issued_date": "2021-08-11T00:00:00",
            
58
  "language": [
48
  "language": [
            
n
n
49
    "es",
            
59
    "en"
50
    "en"
            
60
  ],
51
  ],
            
61
  "license_id": "https://creativecommons.org/licenses/by/4.0/",
52
  "license_id": "https://creativecommons.org/licenses/by/4.0/",
            
62
  "license_title": "https://creativecommons.org/licenses/by/4.0/",
53
  "license_title": "https://creativecommons.org/licenses/by/4.0/",
            
63
  "maintainer": null,
54
  "maintainer": null,
            
64
  "maintainer_email": null,
55
  "maintainer_email": null,
            
65
  "metadata_created": "2024-05-30T15:07:18.449422",
56
  "metadata_created": "2024-05-30T15:07:18.449422",
            
n
66
  "metadata_modified": "2024-05-30T15:07:53.128911",
n
57
  "metadata_modified": "2025-03-03T12:27:43.078736",
            
67
  "multilingual_tags": {
58
  "multilingual_tags": {
            
68
    "en": [
59
    "en": [
            
n
69
      "Visibility",
n

            
70
      "Risk",

            
71
      "Screening",

            
72
      "Controversy",

            
73
      "Hormonal contraception",

            
74
      "Medical profession role",

            
75
      "Adverse drug reactions"

            
76
    ],

            
77
    "es": [

            
78
      "\u00c9tica m\u00e9dica",

            
79
      "Salud de la mujer",

            
80
      "Visibility",
60
      "Visibility",
            
81
      "Risk",
61
      "Risk",
            
82
      "Screening",
62
      "Screening",
            
83
      "Controversy",
63
      "Controversy",
            
84
      "Hormonal contraception",
64
      "Hormonal contraception",
            
85
      "Medical profession role",
65
      "Medical profession role",
            
86
      "Adverse drug reactions"
66
      "Adverse drug reactions"
            
87
    ]
67
    ]
            
88
  },
68
  },
            
89
  "name": 
69
  "name": 
            
90
-risk-in-visible-the-medical-debate-over-non-rare-thrombophilia-nrt-",
70
-risk-in-visible-the-medical-debate-over-non-rare-thrombophilia-nrt-",
            
91
  "notes": null,
71
  "notes": null,
            
92
  "num_resources": 2,
72
  "num_resources": 2,
            
93
  "num_tags": 0,
73
  "num_tags": 0,
            
94
  "organization": {
74
  "organization": {
            
95
    "approval_status": "approved",
75
    "approval_status": "approved",
            
96
    "created": "2023-09-25T13:00:48.436872",
76
    "created": "2023-09-25T13:00:48.436872",
            
97
    "description": "El Instituto de Pol\u00edticas y Bienes 
77
    "description": "El Instituto de Pol\u00edticas y Bienes 
            
98
P\u00fablicos (IPP) es un instituto del CSIC que se cre\u00f3 en 2007, 
78
P\u00fablicos (IPP) es un instituto del CSIC que se cre\u00f3 en 2007, 
            
99
con el objetivo de generar investigaci\u00f3n cient\u00edfica de 
79
con el objetivo de generar investigaci\u00f3n cient\u00edfica de 
            
100
excelencia internacional y de gran impacto social en el \u00e1mbito 
80
excelencia internacional y de gran impacto social en el \u00e1mbito 
            
101
del an\u00e1lisis de las pol\u00edticas p\u00fablicas. \r\n\r\nEl IPP 
81
del an\u00e1lisis de las pol\u00edticas p\u00fablicas. \r\n\r\nEl IPP 
            
102
tiene como misi\u00f3n la generaci\u00f3n de conocimiento 
82
tiene como misi\u00f3n la generaci\u00f3n de conocimiento 
            
103
cient\u00edfico en torno al an\u00e1lisis de pol\u00edticas y bienes 
83
cient\u00edfico en torno al an\u00e1lisis de pol\u00edticas y bienes 
            
104
p\u00fablicos, as\u00ed como su gesti\u00f3n por medio de 
84
p\u00fablicos, as\u00ed como su gesti\u00f3n por medio de 
            
105
organizaciones privadas, instituciones p\u00fablicas y otros actores 
85
organizaciones privadas, instituciones p\u00fablicas y otros actores 
            
106
sociales.",
86
sociales.",
            
107
    "id": "7ee09a95-0735-4848-8c8a-c17381c4278a",
87
    "id": "7ee09a95-0735-4848-8c8a-c17381c4278a",
            
108
    "image_url": "2023-09-25-110048.431222ipp0.png",
88
    "image_url": "2023-09-25-110048.431222ipp0.png",
            
109
    "is_organization": true,
89
    "is_organization": true,
            
110
    "name": "instituto-de-politicas-y-bienes-publicos-ipp-csic",
90
    "name": "instituto-de-politicas-y-bienes-publicos-ipp-csic",
            
111
    "state": "active",
91
    "state": "active",
            
112
    "title": "Instituto de Pol\u00edticas y Bienes P\u00fablicos 
92
    "title": "Instituto de Pol\u00edticas y Bienes P\u00fablicos 
            
113
(IPP), CSIC",
93
(IPP), CSIC",
            
114
    "type": "organization"
94
    "type": "organization"
            
115
  },
95
  },
            
116
  "owner_org": "7ee09a95-0735-4848-8c8a-c17381c4278a",
96
  "owner_org": "7ee09a95-0735-4848-8c8a-c17381c4278a",
            
117
  "private": false,
97
  "private": false,
            
t
118
  "publisher": "7ee09a95-0735-4848-8c8a-c17381c4278a",
t
98
  "proyecto": {},
            
99
  "publisher": "b627d71d-2315-4e75-afc9-897da84459f0",
            
119
  "reference": [
100
  "reference": [
            
120
    "http://vocabularies.unesco.org/thesaurus/concept1014",
101
    "http://vocabularies.unesco.org/thesaurus/concept1014",
            
121
    "http://vocabularies.unesco.org/thesaurus/concept11771"
102
    "http://vocabularies.unesco.org/thesaurus/concept11771"
            
122
  ],
103
  ],
            
123
  "relationships_as_object": [],
104
  "relationships_as_object": [],
            
124
  "relationships_as_subject": [],
105
  "relationships_as_subject": [],
            
125
  "resources": [
106
  "resources": [
            
126
    {
107
    {
            
127
      "byte_size": "762,68 kB",
108
      "byte_size": "762,68 kB",
            
128
      "cache_last_updated": null,
109
      "cache_last_updated": null,
            
129
      "cache_url": null,
110
      "cache_url": null,
            
130
      "created": "2024-05-30T15:07:39.741677",
111
      "created": "2024-05-30T15:07:39.741677",
            
131
      "datastore_active": false,
112
      "datastore_active": false,
            
132
      "description": null,
113
      "description": null,
            
133
      "format": "pdf",
114
      "format": "pdf",
            
134
      "hash": "",
115
      "hash": "",
            
135
      "id": "64984dde-89cf-45f4-b74b-667fb64f01c9",
116
      "id": "64984dde-89cf-45f4-b74b-667fb64f01c9",
            
136
      "last_modified": null,
117
      "last_modified": null,
            
137
      "metadata_modified": "2024-05-30T15:07:53.015646",
118
      "metadata_modified": "2024-05-30T15:07:53.015646",
            
138
      "mimetype": "application/pdf",
119
      "mimetype": "application/pdf",
            
139
      "mimetype_inner": null,
120
      "mimetype_inner": null,
            
140
      "name": 
121
      "name": 
            
141
"Appraising_screening_making_risk_in-visible_dataset.pdf",
122
"Appraising_screening_making_risk_in-visible_dataset.pdf",
            
142
      "name_translated": {
123
      "name_translated": {
            
143
        "en": 
124
        "en": 
            
144
"Appraising_screening_making_risk_in-visible_dataset.pdf",
125
"Appraising_screening_making_risk_in-visible_dataset.pdf",
            
145
        "es": 
126
        "es": 
            
146
"Appraising_screening_making_risk_in-visible_dataset.pdf"
127
"Appraising_screening_making_risk_in-visible_dataset.pdf"
            
147
      },
128
      },
            
148
      "package_id": "ede653fb-c1de-47f2-86cb-72b69563eb24",
129
      "package_id": "ede653fb-c1de-47f2-86cb-72b69563eb24",
            
149
      "position": 0,
130
      "position": 0,
            
150
      "resource_identifier": "",
131
      "resource_identifier": "",
            
151
      "resource_relation": [],
132
      "resource_relation": [],
            
152
      "resource_relation-1": "",
133
      "resource_relation-1": "",
            
153
      "resource_type": null,
134
      "resource_type": null,
            
154
      "size": null,
135
      "size": null,
            
155
      "state": "active",
136
      "state": "active",
            
156
      "url": 
137
      "url": 
            
157
261/247857/1/Appraising_screening_making_risk_in-visible_dataset.pdf",
138
261/247857/1/Appraising_screening_making_risk_in-visible_dataset.pdf",
            
158
      "url_type": null
139
      "url_type": null
            
159
    },
140
    },
            
160
    {
141
    {
            
161
      "byte_size": "2,93 kB",
142
      "byte_size": "2,93 kB",
            
162
      "cache_last_updated": null,
143
      "cache_last_updated": null,
            
163
      "cache_url": null,
144
      "cache_url": null,
            
164
      "created": "2024-05-30T15:07:53.017722",
145
      "created": "2024-05-30T15:07:53.017722",
            
165
      "datastore_active": false,
146
      "datastore_active": false,
            
166
      "description": null,
147
      "description": null,
            
167
      "format": "txt",
148
      "format": "txt",
            
168
      "hash": "",
149
      "hash": "",
            
169
      "id": "1eac16de-d790-4bec-ac0a-da4c5b740d37",
150
      "id": "1eac16de-d790-4bec-ac0a-da4c5b740d37",
            
170
      "last_modified": null,
151
      "last_modified": null,
            
171
      "metadata_modified": "2024-05-30T15:07:53.131162",
152
      "metadata_modified": "2024-05-30T15:07:53.131162",
            
172
      "mimetype": "text/plain",
153
      "mimetype": "text/plain",
            
173
      "mimetype_inner": null,
154
      "mimetype_inner": null,
            
174
      "name": "Appraising_screening_DATASET.txt",
155
      "name": "Appraising_screening_DATASET.txt",
            
175
      "name_translated": {
156
      "name_translated": {
            
176
        "en": "Appraising_screening_DATASET.txt",
157
        "en": "Appraising_screening_DATASET.txt",
            
177
        "es": "Appraising_screening_DATASET.txt"
158
        "es": "Appraising_screening_DATASET.txt"
            
178
      },
159
      },
            
179
      "package_id": "ede653fb-c1de-47f2-86cb-72b69563eb24",
160
      "package_id": "ede653fb-c1de-47f2-86cb-72b69563eb24",
            
180
      "position": 1,
161
      "position": 1,
            
181
      "resource_identifier": "",
162
      "resource_identifier": "",
            
182
      "resource_relation": [],
163
      "resource_relation": [],
            
183
      "resource_relation-1": "",
164
      "resource_relation-1": "",
            
184
      "resource_type": null,
165
      "resource_type": null,
            
185
      "size": null,
166
      "size": null,
            
186
      "state": "active",
167
      "state": "active",
            
187
      "url": 
168
      "url": 
            
188
al.csic.es/bitstream/10261/247857/4/Appraising_screening_DATASET.txt",
169
al.csic.es/bitstream/10261/247857/4/Appraising_screening_DATASET.txt",
            
189
      "url_type": null
170
      "url_type": null
            
190
    }
171
    }
            
191
  ],
172
  ],
            
192
  "spatial": [],
173
  "spatial": [],
            
193
  "state": "active",
174
  "state": "active",
            
194
  "tags": [],
175
  "tags": [],
            
195
  "theme": [
176
  "theme": [
            
196
    
177
    
            
197
"http://datos.gob.es/kos/sector-publico/sector/ciencia-tecnologia",
178
"http://datos.gob.es/kos/sector-publico/sector/ciencia-tecnologia",
            
198
    "http://datos.gob.es/kos/sector-publico/sector/cultura-ocio",
179
    "http://datos.gob.es/kos/sector-publico/sector/cultura-ocio",
            
199
    "http://datos.gob.es/kos/sector-publico/sector/educacion",
180
    "http://datos.gob.es/kos/sector-publico/sector/educacion",
            
200
    "http://datos.gob.es/kos/sector-publico/sector/salud",
181
    "http://datos.gob.es/kos/sector-publico/sector/salud",
            
201
    "http://datos.gob.es/kos/sector-publico/sector/sector-publico"
182
    "http://datos.gob.es/kos/sector-publico/sector/sector-publico"
            
202
  ],
183
  ],
            
203
  "title": "Appraising screening, making risk in/visible. The medical 
184
  "title": "Appraising screening, making risk in/visible. The medical 
            
204
debate over Non-Rare Thrombophilia (NRT) testing before prescribing 
185
debate over Non-Rare Thrombophilia (NRT) testing before prescribing 
            
205
the pill",
186
the pill",
            
206
  "title_translated": {
187
  "title_translated": {
            
207
    "en": "Appraising screening, making risk in/visible. The medical 
188
    "en": "Appraising screening, making risk in/visible. The medical 
            
208
debate over Non-Rare Thrombophilia (NRT) testing before prescribing 
189
debate over Non-Rare Thrombophilia (NRT) testing before prescribing 
            
209
the pill",
190
the pill",
            
210
    "es": "Appraising screening, making risk in/visible. The medical 
191
    "es": "Appraising screening, making risk in/visible. The medical 
            
211
debate over Non-Rare Thrombophilia (NRT) testing before prescribing 
192
debate over Non-Rare Thrombophilia (NRT) testing before prescribing 
            
212
the pill"
193
the pill"
            
213
  },
194
  },
            
214
  "type": "dataset",
195
  "type": "dataset",
            
215
  "url": null,
196
  "url": null,
            
216
  "version": null
197
  "version": null
            
217
}
198
}